MMP expression in leaking filtering blebs and tears after glaucoma filtering surgery.
| Title: | MMP expression in leaking filtering blebs and tears after glaucoma filtering surgery. |
|---|---|
| Authors: | Mathalone N; Department of Ophthalmology, Carmel Medical Center, Haifa, 34362, Israel. matnurit@yahoo.com; Marmor S; Rahat MA; Lahat N; Oron Y; Geyer O |
| Source: | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Graefes Arch Clin Exp Ophthalmol] 2011 Jul; Vol. 249 (7), pp. 1047-55. Date of Electronic Publication: 2011 Mar 31. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 8205248 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-702X (Electronic) Linking ISSN: 0721832X NLM ISO Abbreviation: Graefes Arch Clin Exp Ophthalmol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Berlin ; New York : Springer-Verlag, c1982- |
| MeSH Terms: | Trabeculectomy*; Conjunctiva/*physiology ; Eye Proteins/*metabolism ; Glaucoma, Open-Angle/*enzymology ; Metalloproteases/*metabolism ; Tears/*enzymology; Alkylating Agents/administration & dosage ; Conjunctiva/surgery ; Fistula/enzymology ; Glaucoma, Open-Angle/surgery ; Matrix Metalloproteinase 2/metabolism ; Matrix Metalloproteinase 9/metabolism ; Mitomycin/administration & dosage ; Tissue Inhibitor of Metalloproteinase-1/metabolism ; Tissue Inhibitor of Metalloproteinase-2/metabolism ; Wound Healing/drug effects ; Aged ; Aged, 80 and over ; Blotting, Western ; Female ; Humans ; Immunoenzyme Techniques ; Male ; Middle Aged |
| Abstract: | Objective: Glaucoma filtering surgery may be compromised by cystic blebs which develop more frequently when anti-metabolites are used to arrest wound healing. Matrix metalloproteinases (MMPs) and the naturally occurring tissue inhibitors of metalloproteinases (TIMPs) are essential in connective tissue remodeling and wound healing. This study aimed to determine whether filtering blebs display increased expression of MMP-2, MMP-9, TIMP-1 and TIMP-2, and whether it is reflected in tear fluid.; Methods: Tissue samples from leaking blebs (n = 5) and control conjunctiva (n = 5) were evaluated by immunohistochemistry for MMP-2, MMP-9, TIMP-1 and TIMP-2. Tear fluid was collected from 12 patients (12 eyes) with cystic blebs and ten patients (ten eyes) with flat blebs following trabeculectomy with Mitomycin C applied and 16 controls. MMP levels were evaluated by zymography and TIMP levels by Western blot analysis.; Results: Conjunctival tissue was obtained from five eyes with cystic leaking blebs and five control eyes undergoing cataract surgery. More extensive MMP-2 and MMP-9 expression was found in the epithelial and stromal layers of blebs than in control conjunctiva. TIMP-1and TIMP-2 were expressed in all layers of the blebs, but only in the epithelium of control conjunctiva. MMP-2 and proMMP-2 activity in tears from eyes with flat blebs was significantly higher than that of controls, while activity in tears of eyes with cystic blebs was significantly higher than in those with flat blebs. There was no difference in MMP-9 activity between tears of control and post-filtering surgery eyes.; Conclusions: Increased MMPs and TIMPs expression is associated with the formation of filtering blebs, suggesting involvement of MMPs in bleb remodeling. MMP-2 and ProMMP-2 levels in tear fluid may be markers for bleb configuration. |
| References: | Arq Bras Oftalmol. 2006 Mar-Apr;69(2):161-4. (PMID: 16699663); Curr Eye Res. 1998 Feb;17(2):174-82. (PMID: 9523096); Ophthalmology. 2000 Sep;107(9):1681-7. (PMID: 10964829); Graefes Arch Clin Exp Ophthalmol. 2007 May;245(5):725-32. (PMID: 17024442); Invest Ophthalmol Vis Sci. 2009 May;50(5):2161-4. (PMID: 19117928); J Glaucoma. 2004 Dec;13(6):486-91. (PMID: 15534474); Jpn J Ophthalmol. 2003 Sep-Oct;47(5):423-6. (PMID: 12967855); Exp Eye Res. 2005 Oct;81(4):429-36. (PMID: 16185954); Graefes Arch Clin Exp Ophthalmol. 2007 Mar;245(3):369-75. (PMID: 17043809); Hum Reprod. 1999 Aug;14(8):2089-96. (PMID: 10438431); FASEB J. 1991 May;5(8):2145-54. (PMID: 1850705); Ophthalmic Res. 2008 Oct;40(6):315-21. (PMID: 18688174); J Glaucoma. 2001 Jun;10(3):237-49. (PMID: 11442190); Curr Eye Res. 2006 Feb;31(2):129-36. (PMID: 16500763); Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4588-96. (PMID: 19420332); J Glaucoma. 2006 Oct;15(5):432-6. (PMID: 16988607); Jpn J Ophthalmol. 2007 Sep-Oct;51(5):343-346. (PMID: 17926110); Circulation. 2000 Apr 18;101(15):1833-9. (PMID: 10769285); J Vasc Surg. 2007 Apr;45(4):804-11. (PMID: 17398390); Clin Exp Immunol. 1999 Jan;115(1):19-25. (PMID: 9933416); Ophthalmic Surg Lasers. 1999 May;30(5):367-74. (PMID: 10334024); Br J Surg. 1997 Feb;84(2):160-6. (PMID: 9052425); Arch Ophthalmol. 2002 Mar;120(3):297-300. (PMID: 11879132); Br J Ophthalmol. 2004 Jan;88(1):99-103. (PMID: 14693784); Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3462-7. (PMID: 20207965); J Vasc Interv Radiol. 2008 Apr;19(4):587-94. (PMID: 18375305); Curr Opin Ophthalmol. 2000 Apr;11(2):112-5. (PMID: 10848216); Am J Ophthalmol. 2002 Oct;134(4):521-8. (PMID: 12383808); Ophthalmic Res. 2007;39(6):315-24. (PMID: 17957131); Neurosci Lett. 1997 Nov 28;238(1-2):53-6. (PMID: 9464653); J Glaucoma. 2003 Jun;12(3):266-71. (PMID: 12782847); Am J Pathol. 2001 Oct;159(4):1255-62. (PMID: 11583953); Vet Ophthalmol. 2000;3(2-3):111-119. (PMID: 11397292); Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4142-9. (PMID: 11095607); Ophthalmology. 2002 Jul;109(7):1336-41; discussion 1341-2. (PMID: 12093659); Br J Ophthalmol. 2000 Dec;84(12):1338-9. (PMID: 11090468); Vet Ophthalmol. 2004 Nov-Dec;7(6):397-405. (PMID: 15511281); Invest Ophthalmol Vis Sci. 2003 May;44(5):2163-70. (PMID: 12714657); Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1097-103. (PMID: 12601035); J Leukoc Biol. 2000 Nov;68(5):737-47. (PMID: 11073115); Br J Ophthalmol. 1999 Dec;83(12):1376-83. (PMID: 10574817) |
| Substance Nomenclature: | 0 (Alkylating Agents); 0 (Eye Proteins); 0 (Tissue Inhibitor of Metalloproteinase-1); 0 (tear proteins); 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2); 50SG953SK6 (Mitomycin); EC 3.4.- (Metalloproteases); EC 3.4.24.24 (MMP2 protein, human); EC 3.4.24.24 (Matrix Metalloproteinase 2); EC 3.4.24.35 (Matrix Metalloproteinase 9) |
| Entry Date(s): | Date Created: 20110401 Date Completed: 20110826 Latest Revision: 20220318 |
| Update Code: | 20260130 |
| DOI: | 10.1007/s00417-011-1658-0 |
| PMID: | 21452038 |
| Database: | MEDLINE |
Journal Article